Literature DB >> 9169567

Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer.

S Kosuda1, P V Kison, R Greenough, H B Grossman, R L Wahl.   

Abstract

The purpose of this study was to assess the feasibility of imaging of bladder cancer with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scanning. We studied 12 patients with histologically proven bladder cancer who had undergone surgical procedures and/or radiotherapy. Retrograde irrigation of the urinary bladder with 1000-3710 ml saline was performed during nine of the studies. Dynamic and static PET images were obtained, and standardized uptake value images were reconstructed. FDG-PET scanning was true-positive in eight patients (66.7%), but false-negative in four (33.3%). Of 20 organs with tumor mass lesions confirmed pathologically or clinically, 16 (80%) were detected by FDG-PET scanning. FDG-PET scanning detected all of 17 distant metastatic lesions and two of three proven regional lymph node metastases. FDG-PET was also capable of differentiating viable recurrent bladder cancer from radiation-induced alterations in two patients. In conclusion, these preliminary data indicate the feasibility of FDG-PET imaging in patients with bladder cancer, although a major remaining pitfall is intense FDG accumulation in the urine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169567     DOI: 10.1007/BF00841398

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  17 in total

1.  MR staging of bladder carcinoma: correlation with pathologic findings.

Authors:  J N Buy; A A Moss; C Guinet; M A Ghossain; L Malbec; L Arrive; D Vadrot
Journal:  Radiology       Date:  1988-12       Impact factor: 11.105

2.  Reliability of CT in preoperative evaluation of bladder carcinoma.

Authors:  M Nurmi; K Katevuo; P Puntala
Journal:  Scand J Urol Nephrol       Date:  1988

Review 3.  Diagnostic imaging of urothelial cancer.

Authors:  E J Lantz; R R Hattery
Journal:  Urol Clin North Am       Date:  1984-11       Impact factor: 2.241

4.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  R L Wahl; R L Cody; G D Hutchins; E E Mudgett
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

5.  Routine production of 2-deoxy-2-[18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin.

Authors:  S A Toorongian; G K Mulholland; D M Jewett; M A Bachelor; M R Kilbourn
Journal:  Int J Rad Appl Instrum B       Date:  1990

6.  Staging urinary bladder cancer: value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences.

Authors:  J O Barentsz; G Jager; J P Mugler; G Oosterhof; H Peters; L T van Erning; S H Ruijs
Journal:  AJR Am J Roentgenol       Date:  1995-01       Impact factor: 3.959

7.  Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography.

Authors:  J V Harney; R L Wahl; M Liebert; D E Kuhl; G D Hutchins; G Wedemeyer; H B Grossman
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

8.  Glucose utilization in vivo by human pulmonary neoplasms.

Authors:  K B Nolop; C G Rhodes; L H Brudin; R P Beaney; T Krausz; T Jones; J M Hughes
Journal:  Cancer       Date:  1987-12-01       Impact factor: 6.860

9.  Transurethral ultrasonographic assessment of bladder carcinoma: its value and limitation.

Authors:  M Koraitim; B Kamal; N Metwalli; Y Zaky
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

10.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma.

Authors:  M Rodriguez; S Rehn; H Ahlström; C Sundström; B Glimelius
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  26 in total

Review 1.  Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy.

Authors:  Cory M Hugen; Vinay Duddalwar; Siamak Daneshmand
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

Review 2.  New imaging modalities in bladder cancer.

Authors:  Mansi A Saksena; Douglas M Dahl; Mukesh G Harisinghani
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Authors:  Andrea B Apolo; Jamie Riches; Heiko Schöder; Oguz Akin; Alisa Trout; Matthew I Milowsky; Dean F Bajorin
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.

Authors:  Pierpaolo Alongi; Federico Caobelli; Roberta Gentile; Alessandro Stefano; Giorgio Russo; Domenico Albano; Sergio Baldari; Maria Carla Gilardi; Massimo Midiri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-26       Impact factor: 9.236

5.  FDG-PET for preoperative staging of bladder cancer.

Authors:  O Drieskens; R Oyen; H Van Poppel; Y Vankan; P Flamen; L Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-31       Impact factor: 9.236

Review 6.  [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].

Authors:  S Machtens; A R Boerner; M Hofmann; W H Knapp; U Jonas
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

7.  Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers.

Authors:  S Harkirat; Ss Anand; Mj Jacob
Journal:  Indian J Radiol Imaging       Date:  2010-02

8.  Recurrent urinary bladder paraganglioma.

Authors:  Ali A Al-Zahrani
Journal:  Adv Urol       Date:  2010-06-27

9.  PET/CT and MRI in Bladder Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  J Cancer Sci Ther       Date:  2012-07-30

Review 10.  Current role of PET, CT, MR for invasive bladder cancer.

Authors:  Nathan Lawrentschuk; Sze Ting Lee; Andrew M Scott
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.